廣發証券入選首批「跨境理財通」券商業務試點名單 助力大灣區金融市場互聯互通

香港, 2024年11月1日 - (亞太商訊 via SeaPRwire.com) - 11月1日,首批券商「跨境理財通」業務試點名單正式公佈,廣發証券成功入選,成為首批獲得業務試點參與資格的14家證券公司之一。這一重要里程碑標誌著廣發証券在深化粵港澳大灣區金融合作、助力居民財富跨境配置方面又邁出了堅實的一步。自2月26日《粵港澳大灣區「跨境理財通」業務試點實施細則》正式實施以來,「跨境理財通」已邁入2.0階段。升級後的「跨境理財通」為粵港澳大灣區內地和港澳投資者提供了正式且便捷的渠道,允許個人投資者直接跨境開設和操作投資賬戶,資金的匯劃均使用人民幣跨境結算,進一步豐富了兩地居民的理財產品選擇。「跨境理財通」首批券商試點名單公佈,標誌著該業務試點參與主體進一步拓寬,證券公司將在監管指引下有序加入「跨境理財通」業務中。作為深耕大灣區多年的行業領先券商,廣發証券積極響應並參與「跨境理財通」業務試點,為粵港澳大灣區金融合作創新措施貢獻應有之力。廣發証券在大灣區擁有深厚的客戶基礎,並致力於為試點客戶提供更優的財富管理服務。入選「跨境理財通」業務試點後,廣發証券將重點做好以下三方面的工作,為客戶帶來具有廣發特色的「跨境理財通」客戶服務:一是從集團層面自上而下推進業務佈局,以境內外高效的業務聯動,全力做好境內外客戶的綜合服務。廣發証券集團國際業務佈局較為完善,以集團研究實力引領產品規劃及資產配置方向,統籌集團境內外的資產管理機構優勢資源,構建全天候、多元化的產品供給體系。通過綜合化的財富管理解決方案,全面匹配客戶的境內外綜合投資需求。二是以業內領先的財富管理服務,為投資者優中選優,充分滿足投資者跨境投資多元化配置的需要。近年來,廣發証券踐行以研究為驅動的買方投顧理念,專注於服務客戶財富保值增值需求,在研究、資產管理、財富管理等核心業務領域均取得行業領先優勢。公司配置了超過50人的資產配置研究團隊,匯聚財富管理專業研究力量,以大類資產配置理念為先導,為投資者在全市場精選優秀的資產管理人,滿足投資者個性化的財富管理需求。同時,廣發証券擁有一支超過4,400人的專業投資顧問團隊,全方位觸達客戶的財富管理服務需求。近日,21世紀資管研究院發佈的對11家頭部基金銷售機構的選品能力測評顯示,廣發証券合作的基金公司數量在8家券商和銀行中位列第一;在基金選品業績指標方面,上述測評顯示,廣發証券在11家機構中排名第一,無論是在股票型基金還是債券型基金的選品收益率指標上均表現優異。三是通過快速回應的線上投資運營體驗,為客戶提供更為敏捷的全流程跨境服務。廣發證券將全力提升線上服務效率,為客戶提供操作更為便捷的投資體驗。以完善的線上管道功能,讓投資者可以體驗順暢無礙的「跨境理財通」全流程服務。以南向通為例,符合資質的合格境內投資者可通過易淘金的「跨境理財通」板塊,進入至合作的香港券商業務專區辦理跨境理財通業務。在開戶完成後,客戶將能流覽理財通產品全域,關注心儀的投資產品,及時查閱資產帳戶體系的變化。後續,廣發証券將積極推進業務落地,為促進粵港澳大灣區金融市場互聯互通、拓寬居民投資渠道貢獻力量。廣發証券將繼續發揮自身專業優勢,為粵港澳大灣區居民提供更加優質、便捷的跨境財富管理服務,助力大灣區居民實現財富的保值增值。 Copyright 2024 亞太商訊 via SeaPRwire.com.
More
MWA Renews Learning and Development Contracts with Top Malaysian Institutions ACN Newswire

MWA Renews Learning and Development Contracts with Top Malaysian Institutions

KUALA LUMPUR, Oct 29, 2024 - (ACN Newswire via SeaPRwire.com) - Mogul Works Asia ("MWA"), a leading integrated marketing and talent solutions company in Southeast Asia, is proud to announce the renewal of its learning and development contracts with some of Malaysia's most renowned institutions. This marks a continuation of Mogul Works Asia's efforts to support local upskilling programs as part of the nation's strategy to cultivate a highly skilled and adaptable workforce.The renewed partnerships emphasize Mogul Works Asia's commitment to delivering high-quality learning and development solutions that cater to the needs of Malaysia's evolving economic landscape. Among the organizations that have extended their collaboration with Mogul Works are Khazanah Nasional, Touch 'n Go, CGC, Sime Darby, Sunway Group, Kenanga Investment Bank, and the Employees Provident Fund of Malaysia (KWSP), all of which are integral to Malaysia's growth plans.The founders of Mogul Works Asia, Mr. Lee John Salmon and Tunku Eddy Nasruan Adil, commented: "We are honored to continue our partnerships with these distinguished institutions. Our mission is to help build great people and companies here in Malaysia. We recognize the demand for Malaysian talent globally and aim to provide world-class training and opportunities to encourage that talent to develop within Malaysia."Over the years, Mogul Works Asia has focused on enabling these institutions and their diverse workforces to contribute meaningfully to both national development and regional and global competitiveness. This ongoing commitment positions the company as a key player in the talent development and marketing sectors, contributing to Malaysia's broader goal of establishing itself as a business hub in Southeast Asia.The renewal of these contracts not only strengthens Mogul Works Asia's foothold in the industry but also reflects the growing demand for trusted partners in learning and development, marketing, and employer branding. While specific contract details cannot be disclosed, standard project sizes for Mogul Works Asia range from USD 30,000 to over USD 1 million.Mogul Works Asia continues to support organizations in achieving their growth ambitions by combining specialized talent development, recruitment tools, and marketing expertise. With a focus on democratizing quality education, the company strives to build market leaders and enable more companies to grow their businesses in Malaysia. This is in line with Malaysia's goal of attracting, retaining, and cultivating talent within a rapidly evolving economy.Social LinksFacebook: https://www.facebook.com/mogulworksasia/Instagram: https://www.instagram.com/mogulworksasia/LinkedIn: https://www.linkedin.com/company/mogul-works-asia/tiktok: https://www.tiktok.com/@mogulworksasiaMedia ContactMogul Works AsiaAmalia MohdWebsite: https://www.mogulworks.asia Copyright 2024 ACN Newswire via SeaPRwire.com.
More

新鴻基公司投資於ActusRayPartners新推出的日本阿爾法基金 – ActusRayPartners Japan Alpha Fund

EQS 新聞 via SEAPRWire.com / 2024-11-01 / 13:06 UTC+8 新鴻基有限公司 (香港股份代號:86) (「新鴻基公司」)及旗下持牌基金管理平台Sun Hung Kai Capital Partners Limited欣然宣布,投資於2024年9月26日啓動的ActusRayPartners日本阿爾法基金(ActusRayPartners Japan Alpha Fund)(「該基金」)。這是新鴻基公司繼對ActusRayPartners亞洲及歐洲策略持續投資後的新增投資。其他ActusRayPartners現有客戶也對此日本策略表達了初步的興趣。該基金採用股票長短倉和接近市場中性策略,旨在透過識別及捕捉日本股票市場的低效性來產生阿爾法收益。ActusRayPartners採用其「自主概率投資」(Discretionary Probabilistic Investing)方式,通過結合量化基礎與自主調整,以應對純粹量化交易的盲點。 這是ActusRayPartners繼 2020 年和 2022 年分別成功推出歐洲策略及亞洲策略基金後,再推出的第三隻阿爾法策略基金。歐洲策略基金於2023及2024年榮獲「HFM 歐洲對沖基金表現大獎」,而亞洲策略基金則於2024年榮獲「HFM 亞太區對沖基金表現大獎」。ActusRayPartners是一家總部位於香港的資產管理公司,由安力德 (Andrew Alexander)、陳兆偉(Raymond Chan)和張泓(Patrick Cheung) 於2019年共同平等創立。多位團隊成員曾於麥格理量化對冲基金部門工作。目前, ActusRayPartners在香港及悉尼共擁有27名成員,負責管理亞洲、歐洲及日本逾7億美元的資金。新鴻基公司副行政總裁 Tony Edwards 表示:「恭喜 ActusRayPartners再次推出新基金。自 2020 年以來,新鴻基公司很榮幸能夠提供種子投資以及支持 ActusRayPartners的發展,而這項進一步的承諾強調了我們對其能力的信心,並反映我們之間的投資目標完美契合。」ActusRayPartners的三位共同創始人表示:「日本阿爾法策略的推出對我們而言是一個令人振奮的里程碑。我們衷心感謝新鴻基公司多年來的支持。我們期待運用我們的『自主概率投資』方式,為投資者捕捉日本股票市場的阿爾法收益。」高盛和摩根士丹利是 ActusRayPartners日本阿爾法基金的主要經紀商。Morgan Stanley Fund Services和開曼群島羅兵咸永道會計師事務所分別是該基金的管理人和核數師。高偉紳律師事務所和滙嘉律師事務所分別是其國際法律顧問和開曼群島法律顧問。 – 完 – 關於ActusRayPartnersActusRayPartners是一家總部位於香港的資產管理公司,由安力德 (Andrew Alexander)、陳兆偉(Raymond Chan)和張泓(Patrick Cheung) 於2019年共同平等創立。多位團隊成員曾於麥格理量化對冲基金部門工作。目前, ARP在香港及悉尼共擁有27名成員,負責管理亞洲、歐洲及日本逾7億美元的資金。ActusRayPartners採用的「自主概率投資」方式綜合了:1)量化基礎;以及2)自主調整去應對量化投資的盲點。量化基礎使用了基本面、分析員預測、技術及另類數據,並採用高級統計、自然語言處理及人工智能模型。投資經理的自主調整工作專注於應對純粹量化投資的挑戰,而非單純基本面、宏觀或資金流動分析。關於新鴻基有限公司 及 Sun Hung Kai Capital Partners新鴻基有限公司 (香港股份代號:86) (「新鴻基公司」/「本公司」,連同其附屬公司「本集團」) 是一家領先的香港金融機構,在另類投資和財富管理領域備受肯定。新鴻基公司成立於1969年,其多元化的投資組合,涵蓋公開市場、信貸和另類投資策略(其中包括房地產和私募股權),締造長期經風險調整回報。憑藉其紮根亞洲的傳承,新鴻基公司支持和培育該地區優秀且具專業能力的新晉資產管理公司,賦能他們實現卓越表現。集團亦利用其長久以來建立的投資業務專長和豐富資源,透過其家族辦公室解決方案,為理念一致的合作伙伴和超高淨值投資者提供量身定制的投資解決方案。截至2024年6月30日,集團的資產總值約為395億港元。 有關新鴻基有限公司更多的資訊,請瀏覽 www.shkco.com 或關注公司領英。Sun Hung Kai Capital Partners成立於2020年,是新鴻基有限公司旗下受香港證監會監管的子公司,持有第一、四及九類牌照。有關詳情,請瀏覽 www.shkcapital.com 或於領英關注Sun Hung Kai Capital Partners。媒體查詢,請聯絡:偉達公共關係顧問林貴珍 +852 9839 6552張夢瑩 +852 9794 5751電郵:SHKCo@hkstrategies.com 2024-11-01 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php
More
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status JCN Newswire

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., Nov 1, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). If the FDA accepts the BLA, the Prescription Drug User Fee Act (PDUFA) action date (target date for completion of examination) will be set.The BLA is based on data from the Clarity AD (Study 301) open-label extension (OLE) and modeling of observed data. If approved by the FDA, the LEQEMBI autoinjector could be used to administer LEQEMBI at home or at medical facilities, and the injection process is expected on average to take about 15 seconds. As part of the subcutaneous autoinjector 360 mg weekly maintenance regimen under review, patients who have completed the biweekly intravenous (IV) initiation phase would receive weekly doses that maintain effective drug concentrations to sustain the clearance of highly toxic protofibrils* which can continue to cause neuronal injury even after the amyloid-beta (Aβ) plaque has been cleared from the brain.AD is an ongoing neurotoxic process that begins before and continues after plaque deposition. Data suggest that early and continuing treatment may prolong the benefit of therapy even after plaque is cleared from the brain. This SC autoinjector is expected to be easier for patients and their care partners to use and may reduce the need for hospital or infusion site visits and nursing care compared to IV administration. In addition to potentially maintaining the clinical and biomarker benefits, subcutaneous maintenance dosing may be more convenient for patients and their care partners to continue the treatment.LEQEMBI is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, UAE and Great Britain. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU). The US FDA accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly LEQEMBI IV maintenance dosing in June 2024 and set a PDUFA action date for January 25, 2025.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.* Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline associated with this progressive, debilitating condition.1 Protofibrils cause injury to neurons in the brain, which in turn, can negatively impact cognitive function via multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.2INDICATIONLEQEMBI® [(lecanemab-irmb) 100 mg/mL injection for intravenous use] is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.For the full press release, visit https://www.eisai.com/news/2024/news202482.html. About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S.,3 Japan,4 China,5 South Korea,6 Hong Kong,7 Israel,8 the United Arab Emirates9 and Great Britain.10 Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU).LEQEMBI’s approvals in these countries was based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.11,12 The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P
More
健倍苗苗發佈盈喜 預期股東應佔綜合溢利增加不少於50% ACN Newswire

健倍苗苗發佈盈喜 預期股東應佔綜合溢利增加不少於50%

香港, 2024年11月1日 - (亞太商訊 via SeaPRwire.com) - 健倍苗苗(保健)有限公司(「健倍苗苗」或「公司」;股份代號:2161,連同其附屬公司統稱「集團」)為香港品牌保健品的領先營銷商及分銷商,集團今天發佈盈喜預告。根據對本集團截至二零二四年九月三十日止六個月的未經審核綜合管理賬目的初步審閱及董事會目前可得的資料,本集團預期截至二零二四年九月三十日止六個月的股東應佔綜合溢利(「綜合溢利」)將較去年同期增加不少於50%。綜合溢利大幅增加主要受惠於集團核心品牌的強勁銷售勢能,尤其是品牌藥分部的何濟公和品牌中藥分部的保濟丸。此外,集團的濃縮中藥顆粒業務持續增長也提供進一步支持。這樣的亮眼表現反映集團的線下及線上渠道銷售及營銷策略行之有效,從而把握品牌消費保健產品於香港、澳門及大灣區市場的增長潛力。健倍苗苗擁有多元化產品組合,包括品牌藥、品牌中藥以及健康保健品。集團持續推進重點策略,其中包括擴展本地和跨境電子商務平台、於香港及大灣區市場中發掘傳統中藥的機遇、優化產品組合以迎合消費趨勢、發揮品牌管理優勢,以及加強集團的商業執行力。詳情請參閱香港交易所之公告。有關健倍苗苗(保健)有限公司 (股份代號:2161)健倍苗苗是設於香港的品牌醫療保健品推廣及分銷公司,產品據點遍及大中華、東南亞及其他選定國家。集團擁有豐富的行銷專業知識並具備深厚的製藥背景,秉承產品功效和品質至上的優良傳統,在行業內定位獨特,致力於滿足消費者的保健需要。作為本地領先的品牌醫療保健品運營商,集團擁有一廣泛系列品牌醫療保健品,包括品牌藥、品牌中藥及健康保健品,其中包括「保濟丸」、「何濟公止痛退熱散」、「德國秀碧除疤膏」、「美德瑪寶兒除疤啫喱」、「唐太宗活絡油」、「飛鷹活絡油」、「十靈丹」、「十靈油」及「鎮痛霸祛風活絡油」等家喻戶曉的傳統品牌。而自2021年 5月27日,集團獲納入 MSCI 香港微型股指數成份股。有關集團詳情,請瀏覽:www.jbmhealthcare.com.hk Copyright 2024 亞太商訊 via SeaPRwire.com.
More
Birch Creek 與 KKR 完成 1.5 億美元信貸融資 Business

Birch Creek 與 KKR 完成 1.5 億美元信貸融資

(SeaPRwire) - 融資所得將用於支持超過 4GW 太陽能專案的開發 聖路易斯, 2024 年 10 月 31 日 — Birch Creek Energy, LLC(「Birch Creek」),一家公用事業規模太陽能和儲能開發商和獨立發電廠,以及 KKR,一家領先的全球投資公司,今天宣布 Birch Creek 已通過 KKR 管理的保險帳戶在 KKR 的高收益資產基礎融資 (ABF) 策略中關閉了 1.5 億美元 的信貸額度。該融資擴展並擴大了 Birch Creek 此前 1 億美元 的額度,將用於為公司開發組合中的太陽能電站提供開發費用和設備資金。 Birch Creek 成立於 2019 年,主要專注於在 PJM、MISO 和 ERCOT 等高價值、流動性市場中的配電級公用事業規模太陽能和儲能策略。該公司擁有龐大的管道,以及在後期資產出售和 IPP 增長方面取得了成功業績。Birch Creek 目前在其獨立發電廠擁有 160 兆瓦的運營專案,另外 187 兆瓦正在建設中,將於 2024 年最後 2 個月投入使用,總計達到 347 兆瓦。 「我們很興奮能夠通過我們信貸額度的續簽和擴大來加強我們與 KKR 的關係,」Birch Creek 首席執行官 丹·西格爾 表示。「通過該額度,我們能夠繼續在某些核心市場開發太陽能專案,同時也為更接近建設的專案提供一些設備採購資金。我們很自豪能與 KKR 合作,感謝他們對我們平台的信任,因為我們將繼續發展我們獨特的快速上市策略。」 「在全球對清潔能源和儲能解決方案需求日益增長的背景下,我們很高興能夠通過我們的高收益 ABF 策略,為 Birch Creek 提供這種增強的信貸額度,以進一步發展其太陽能和儲能專案管道,」KKR 主任 埃裡希·海因岑 表示。 關於 Birch Creek EnergyBirch Creek Energy 是一個公用事業規模太陽能開發平台,在 美國 開發、融資和擁有公用事業規模太陽能和儲能專案。自 2019 年以來,Birch Creek Energy 已開發了 1.7 吉瓦 (GW) 的太陽能專案,並在 MISO、PJM、ERCOT 和東南部的各個開發和運營階段擁有超過 14.2 吉瓦 (GW) 的公用事業規模太陽能和儲能專案。Birch Creek Energy 擁有 56 名員工,總部位於密蘇里州 聖路易斯。如需了解更多資訊,請訪問 。 關於 KKRKKR 是一家領先的全球投資公司,提供另類資產管理以及資本市場和保險解決方案。KKR 旨在通過遵循耐心和紀律的投資方法,僱用世界一流的人才,以及支持其投資組合公司和社區的增長,來創造有吸引力的投資回報。KKR 贊助的投資基金投資於私募股權、信貸和實物資產,並擁有管理對沖基金的戰略合作夥伴。KKR 的保險子公司在全球大西洋金融集團的管理下提供退休金、人壽和再保險產品。對 KKR 投資的引用可能包括其贊助基金和保險子公司的活動。如需了解有關 KKR & Co. Inc. 的更多資訊,請訪問 KKR 網站:。如需了解有關全球大西洋金融集團的更多資訊,請訪問全球大西洋金融集團網站:。 SOURCE Birch Creek Energy本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
環球時報:故宮博物院新館主體結構接近完工 Business

環球時報:故宮博物院新館主體結構接近完工

(SeaPRwire) - 北京, 2024 年 10 月 31 日 — 北京日報周二報導,位於北京海淀區的故宮博物院新館,其主要結構預計在 2024 年底前完成主要結構里程碑。 故宮博物院北館的建設是該機構百年發展中的標誌性事件,必將對其產生深遠而持久的影響。故宮博物院院長王旭東周二在一個活動中表示,北館建成後,將顯著提升博物館在文物保護、研究和公眾參與方面的能力。 新的設施將提供先進的保護和展示選項,使文物得到更科學的保護和更有效的展出。王旭東指出,北館預計將增強國際合作,讓中國文化成就得到更廣泛的分享,促進全球文化交流。 這個新館佔地面積超過 10 萬平方米,擁有多項先進的設施,以便更好地保護文物,例如展品的防震保護、恆溫恆濕監控和照明系統。 北館內部將設置超過 300 個隔震和減震元件,保護建築及其無價文物免受地震活動的影響。 國家一級註冊結構工程師李雲周三告訴《環球時報》,通過利用高科技建築材料和施工技術,建築物的安全性得到了提高,從而為文化遺產提供了更好的保護。 “創新的鋁合金屋面不僅保留了傳統建築的風格,而且保證了建築物在未來很多年都保持新貌,”李雲指出。 北館建築使用的混凝土採用仿生自修復技術。當出現小於 0.6 毫米的裂縫時,這種特殊的混凝土可以“自愈”,顯著延長建築物的使用壽命。 李雲表示,自修復混凝土顯著增強了文化遺產的保護,並降低了維護成本。 新博物館預計在 2025 年故宮博物院成立 100 週年之際竣工。 北館的擴建旨在緩解北京市中心故宮博物院面臨的空間限制,讓更多文物得以展出,並為文化工作者提供專門的修復區域。 故宮博物院副院長杜海江告訴《人民日報》,建成後,每年展出的文物數量將達到 2 萬至 3 萬件。 SOURCE Global Times本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Guidehouse Insights 預計全球工業沼氣市場未來十年將大幅加速 Business

Guidehouse Insights 預計全球工業沼氣市場未來十年將大幅加速

(SeaPRwire) - 當今工業生物氣體領域的最大驅動力是政府政策、激勵措施和資金計畫的結合 BOULDER, 科羅拉多州, 2024年10月31日 — 一份來自 的最新報告調查了全球工業建築和應用生物氣體市場。 生物氣體在幫助工業活動脫碳方面具有巨大潛力,這些活動難以在沒有燃料燃燒的情況下進行,但迄今為止,巨大的障礙限制了市場的發展。根據 Guidehouse Insights 的一份新報告,隨著脫碳政策、碳定價法規、邊境碳調整以及其他應對碳污染的措施對化石燃料施加經濟壓力,工業生物氣體市場預計在未來十年將顯著加速。Guidehouse Insights 預計,工業生物氣體的年需求量將從 2024 年的 666.9 億立方英尺 (BCF) 增長到 2033 年的 2,042.4 BCF,複合年增長率 (CAGR) 為 13.2%。 “在當今全球用於工業應用的生物氣體中,大約三分之二被轉換為可再生天然氣 (RNG),用於任何原本使用化石氣體的應用。剩餘的工業生物氣體用於發電、過程供熱或熱電聯產,通常在產生生物氣體的現場使用,”Guidehouse Insights 的研究分析師 Grant Samms 表示。“垃圾填埋場和廢水處理場等市政設施以及農業運營是工業生物氣體的最大生產者,儘管每個來源的突出程度因地理區域而異。” 到目前為止,工業生物氣體領域的最大驅動力是政府政策,包括對生物氣體開發的財政激勵措施和排放水平的監管。其他驅動力包括某些地區豐富的適合作物原料以及企業的內部脫碳目標。然而,工業生物氣體市場也面臨著重大的阻力,最突出的是,在許多地方,生物氣體和 RNG 的價格可能是化石氣體的 4 到 6 倍。根據該報告,其他障礙包括將生物氣體升級為 RNG 的顯著額外成本,以及僅為特定應用產生生物氣體提供激勵措施的政策孤島。 該報告, , 審查了全球工業建築生物氣體市場。它分析了當前市場問題、技術趨勢、驅動力、障礙和政策環境。市場分析顯示了收入和銷售單位的數據。分析數據涵蓋到 2033 年,並按技術、價值鏈位置和地區進行細分。該報告的執行摘要可在 上免費下載。 關於 Guidehouse InsightsGuidehouse Insights 是 Guidehouse 專注於市場情報的部門,為當今快速變化的受嚴格監管行業提供研究、數據和基準服務。我們的見解建立在對全球清潔技術市場的深入分析基礎之上。該團隊的研究方法結合了供應方行業分析、最終用戶主要研究和需求評估,並與對技術趨勢的深入研究相結合,以提供對新興彈性基礎設施系統的全面了解。有關 Guidehouse Insights 的更多信息,請訪問 。 關於 GuidehouseGuidehouse 是一家全球諮詢公司,為商業和公共部門提供諮詢、數字和管理服務。Guidehouse 的宗旨是為國家安全、金融服務、醫療保健、能源和基礎設施行業服務。通過其敏捷性、能力和規模,顛覆了傳統的諮詢交付模式,該公司提供技術驅動的、重點突出的解決方案,幫助客戶實現創新、彈性和增長。憑藉高品質標準和對客戶成功的執著追求,Guidehouse 的 17,000 多名員工與領導者合作,以智勝複雜性,實現真正改變未來的轉型變革。 * 本新聞稿中關於報告《工業建築和應用生物氣體》的信息, 僅為摘要,反映了 Guidehouse Insights 基於市場數據和趨勢分析的當前預期。市場預測和預期具有固有的不確定性,實際結果可能與本新聞稿或報告中的結果存在重大差異。請參閱完整報告以全面了解報告結論所依據的假設和用於創建報告的方法。Guidehouse Insights 和 Guidehouse 均不承擔更新本新聞稿或報告中所載信息的任何義務。 欲了解更多信息,請聯繫: Cecile Fradkin,代表 Guidehouse Insights+1.646.941.9139 SOURCE Guidehouse Insights本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
西班牙洪水造成至少 158 人死亡,搜救人員在洪水中尋找遺體 News

西班牙洪水造成至少 158 人死亡,搜救人員在洪水中尋找遺體

(SeaPRwire) - 週四,救援人員在被困的汽車和濕透的建築物中搜尋遺體,居民們從被毀壞的家園中搶救出他們能搶救的東西。此前,特大暴雨引發的洪水奪走了至少 158 條生命,僅瓦倫西亞地區就確認死亡 155 人。週四,從這場史無前例的自然災害留下的瓦礫和無處不在的泥漿中出現了更多可怕的景象,這場災害造成了西班牙有史以來最嚴重的自然災害。災後景象令人想起海嘯的後果,倖存者們一邊哀悼親人,一邊努力重建家園。汽車像倒下的多米諾骨牌一樣堆疊在一起,連根拔起的樹木、倒塌的電線和家用物品都陷在泥漿中,泥漿覆蓋了瓦倫西亞地區數十個社區的街道,瓦倫西亞地區位於巴塞羅那以南。目前尚不清楚有多少人失蹤,可能還會找到更多遇難者。“不幸的是,一些車輛裡有遇難者,”西班牙交通部長奧斯卡·普恩特週四早些時候在死亡人數從週三晚上的 95 人上升之前說道。湍急的水流將狹窄的街道變成死亡陷阱,並形成河流,衝過房屋和企業,沖走了汽車、人員以及其他一切。洪水摧毀了橋樑,使道路面目全非。焊接工路易斯·桑切斯表示,他救下了幾名被困在瓦倫西亞市以南 V-31 公路被洪水淹沒的汽車裡的人。這條道路迅速變成了一片佈滿數百輛汽車的漂浮的墓地。“我看到屍體漂過。我喊了出來,但沒有任何反應,”桑切斯說。“消防員盡可能地先帶走了老人。我住在附近,所以我試圖幫助和營救人們。到處都是哭喊聲,他們都被困住了。”地方當局週三晚些時候表示,直升機上的救援人員救出了約 70 名被困在屋頂和汽車中的人,但地面救援人員還遠沒有完成工作。在週四與瓦倫西亞的官員和緊急救援人員會面後,佩德羅·桑切斯表示:“我們的首要任務是找到遇難者和失蹤者,以便我們幫助結束他們家人的痛苦。”這是為期三天的官方哀悼期的第一天。“非同尋常”的洪水西班牙的地中海沿岸習慣了秋季風暴,這些風暴會造成洪水,但這是有記錄以來最猛烈的暴雨洪水事件。科學家將其與氣候變化聯繫起來,氣候變化也導致西班牙氣溫越來越高,乾旱加劇,地中海海水變暖。根據世界天氣歸因組織週四進行的一項快速但部分分析,人類造成的氣候變化使瓦倫西亞本週暴雨事件的可能性增加了一倍。世界天氣歸因組織由數十名研究全球變暖在極端天氣中的作用的國際科學家組成。西班牙已經遭受了近兩年的乾旱,這意味著當週二晚些時候和週三早些時候發生洪水時,地面非常堅硬,無法吸收雨水,從而導致暴雨洪水。這場猛烈的氣候事件讓地方政府官員措手不及。西班牙國家氣象局表示,瓦倫西亞的奇瓦鎮在八小時內降雨量超過了過去 20 個月的降雨量,稱這場洪水“非同尋常”。在瓦倫西亞市附近的帕伊波爾塔鎮,該鎮有 25,000 人,市長瑪麗貝爾·阿爾巴拉特週四表示,該鎮至少有 62 人遇難。“(帕伊波爾塔)從來沒有發生過洪水,我們從未遇到過這種問題。我們在鎮中心發現了很多老人,”阿爾巴拉特告訴國家廣播公司 RTVE。“還有很多人來把車從車庫裡開出來……這真是個陷阱。”農場受損雖然瓦倫西亞市附近的市鎮遭受了最大的痛苦,但暴風雨在伊比利亞半島南部和東部海岸的大片區域肆虐。在鄰近的卡斯蒂利亞-拉曼恰地區確認死亡 2 人,安達盧西亞南部死亡 1 人。西班牙南部廣泛的溫室和農場因暴雨和洪水而遭到破壞,西班牙南部被稱為歐洲的花園,因為它出口農產品。暴風雨在瓦倫西亞引發了一場怪異的龍捲風,在安達盧西亞引發了一場冰雹暴,在汽車上打出洞。從安達盧西亞的馬拉加西南一直到安達盧西亞,房屋都失去了供水。週四,暴雨繼續向北移動,西班牙氣象局對瓦倫西亞東部卡斯特利翁省的幾個縣以及加泰羅尼亞的塔拉戈納以及西南部的卡迪斯發出了警報。總理說:“這場風暴系統仍在我們身邊。請待在家裡,聽從官方建議,這將有助於挽救生命。”在一片廢墟中繼續搜尋西班牙緊急救援部隊的 1,000 多名士兵加入了地方和地方緊急救援人員,搜尋遇難者和倖存者。軍方緊急救援部隊的安赫爾·馬丁內斯在至少有 6 人死亡的烏蒂埃爾鎮告訴西班牙國家廣播電台 RNE:“我們正在挨家挨戶搜尋。”美聯社記者週四看到救援人員從托雷區的一處地下停車場中移走了 7 具屍袋。兩個鎮的許多居民不得不踩著粘膩的泥漿走很長的路去尋找食物和水。他們的許多汽車都被毀壞了,暴風雨留下的泥漿、破壞和碎片使一些道路無法通行。有些人推著購物車走在濕漉漉的街道上,有些人則背著孩子,以免他們踩到泥漿。瓦倫西亞地區主席卡洛斯·馬松週四詢問西班牙軍隊是否可以幫助向民眾分發基本物品。國家警察在週三逮捕了 39 人,罪名是搶劫。民警部署警官阻止進一步盜竊房屋、汽車和購物中心。西班牙新聞社 EFE 報導,週三瓦倫西亞約有 15 萬人斷電,但到週四,約有一半人恢復了供電。尚不清楚有多少人沒有自來水,他們依靠他們能找到的瓶裝水。該地區仍然部分孤立,多條道路中斷,鐵路中斷,包括通往馬德里的高速鐵路。官員們表示,修復受損的路段需要兩到三週的時間。一名男子哭著向國家廣播公司 RTVE 的一名記者展示了他瓦倫西亞南部卡塔羅哈的住宅一樓的殘骸。看起來好像一顆炸彈在裡面爆炸了,摧毀了家具和財物,並剝掉了部分牆壁的油漆。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More
Standard Uranium Provides Exploration Update Highlighting Successful Project Generation with New Joint Venture Ready Projects Available in 2025 ACN Newswire

Standard Uranium Provides Exploration Update Highlighting Successful Project Generation with New Joint Venture Ready Projects Available in 2025

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - October 31, 2024) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company")is pleased to provide a summary of work programs on three of it's 100% owned uranium exploration projects currently under option and plans for targeted exploration strategies to continue advancing its uranium portfolio in the Athabasca Basin region, northern Saskatchewan towards discovery.The Company holds more than 233,000 acres of prime exploration real estate across the prolific Athabasca Basin region, which hosts the highest-grade uranium deposits on the planet. The Company boasts an attractive portfolio of uranium exploration projects currently available for option ranging from early-stage to drill-ready projects throughout the Athabasca region, providing turn-key opportunities with permits in hand, First Nations agreements signed, vendors secured, and highly prospective uranium targets. Standard Uranium has continued to deliver on its project generator model in 2024 through expansion of landholdings and advancement of early-stage projects through geophysical surveys to be executed this fall, providing excellent turn-key opportunities for potential joint venture partners. The Company is actively seeking new joint venture partners on these exciting uranium projects.Additionally, the Company successfully completed three joint venture earn-in partnerships on the Sun Dog, Canary, and Atlantic projects this year, totalling over $23.8M in work commitments over the next three years. The Company advanced all three projects by successfully operating and completing exploration drill programs on time and under budget. Standard Uranium brings a skilled team of in-house geoscientists and invaluable relationships with First Nations partners and vendors to the table in designing and executing option agreements.2024 Exploration Summary and ObjectivesProject Generator: Completed four definitive option agreements on four projects, securing exploration expenditures and non-dilutive cash-flow into the Company - Sun Dog, Atlantic, Canary, and Brown Lake projects.Aggressive Exploration: Successfully planned and operated three drill programs on Sun Dog, Atlantic, and Canary returning promising results of uranium mineralization and prospective geology, all of which were partner-funded and successfully operated by the Company.Additional Project Advancement: Initial exploration and geophysical programs on the early-stage Rocas and Corvo projects is planned for the fall, creating more opportunities for additional option partnerships.Expanded Landholdings: The Company added nearly 45,000 acres of prospective land to its portfolio in 2024 through low-cost staking, expanding the Ascent and Corvo projects significantly, and adding four new projects to its exploration pipeline in the Athabasca Basin region."We are pleased to share that we are continuing to advance additional uranium exploration projects through targeted geophysical survey work and new staking, which provide more opportunities for new joint venture partners looking to enter the Athabasca Basin. This part of our business represents an outstanding opportunity for companies that want to explore in the world's best uranium jurisdiction with our team at Standard Uranium," said Jon Bey, CEO & Chair of Standard Uranium. "We have built strong relationships with government and our First Nations partners allowing for expediting permitting, along with the key vendors to ensure exploration projects are completed on time and on budget." Figure 1. Overview of the eastern Athabasca Basin region highlighting Standard Uranium's projects under option and available for JV.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10633/228449_c6974358c4f45b18_002full.jpgEastern Athabasca Basin Exploration Highlights & OpportunitiesAtlantic Project - ATCO Mining Option (CSE: ATCM)Uranium Mineralization Confirmed: Analytical results from the winter 2024 drill program at the Project confirmed highly anomalous uranium in drill holes ATL-24-002, ATL-24-004A, and ATL-24-005A, coinciding with prospective structural zones and favorable alteration including dravite-rich clays.Sandstone & Basement-Hosted Uranium: Multiple zones of elevated uranium linked to the sub-Athabasca unconformity and basement structural zones were intersected, indicating a uranium-fertile system.Uranium Pathfinders: Several key uranium pathfinder elements are present in anomalous quantities in multiple drill holes, providing vectoring information for future programs. Intersections of dravitic-clay associated with structural zones has been confirmed in drill holes ATL-24-002, ATL-24-004A, and ATL-24-005A.Verified Targets: Massive structural disruption confirmed in the sandstone column and multiple wide (>10 metres) brittle-reactivated graphitic shear zones confirm the main interpreted electromagnetic ("EM") corridor on the western claim block which was not reached by previous operators. The inaugural program results have confirmed the Company's exploration thesis on the Project, highlighting a uranium-fertile system with several kilometres of still untested strike length across the Project.Follow Up Targets & Next Steps: Atlantic holds significant upside for discovery along the untested portions of the E-W conductor system. Supplementary geophysical surveys over the central claim blocks are currently being planned and will provide further target areas for phase II and III drilling, along with the additional untested gravity low anomalies on the western block identified in 2022.Canary Project - Mamba Exploration Option (ASX: M24)Uranium Mineralization Confirmed: Analytical results from the spring 2024 drill program at the Project confirmed moderately anomalous uranium in drill holes CAN-24-001 and CAN-24-003 with Uranium:Thorium ("U:Th") ratios ≥3:1, indicating hydrothermal uranium input.Basement-Hosted Uranium: Multiple zones of elevated uranium linked to structural zones and/or proximal to lithological contacts, indicating a uranium-fertile system.Elevated Uranium Pathfinders: Several key uranium pathfinder elements are present in anomalous quantities in multiple drill holes within the crystalline basement, providing vectoring information for future programs; anomalous Boron is particularly common. Spectroscopy confirms presence of fracture-hosted dravitic-clay (13.4%) associated with semi-pelitic gneiss in drill hole CAN-24-001.Follow Up Targets & Next Steps: Canary holds significant upside for discovery along three different and significantly underexplored conductor systems. Supplementary geophysical surveys over all three corridors will provide further target areas for phase II and III drilling.Brown Lake - Mustang Energy Acquisition Agreement (CSE: MEC)Project Monetization: Acquired in 2023 via low-cost staking, Standard Uranium sold 90% of the 312-hectare Brown Lake project to Mustang Energy for 60,000 common shares in Mustang and retains a 10% free carried interest in the project, providing future discovery upside potential.Shallow drill targets: 300 counts per second ("cps") were intersected in seven of eight drill holes - Geochemical assays still pending.Prospectivity Model Confirmed: Elevated radioactivity and increased hydrothermal alteration at Wishbone are largely associated with stacked graphitic structural zones, indicating favorable corridors for fluid movement and uranium deposition across the Project akin to other basement-hosted Athabasca deposits.Discovery of Radioactivity: Occurrences of strong to intense radioactivity in outcropping graphitic basement rocks were identified at surface while prospecting at the Wishbone target area:Approximately five kilometres of strike length along a regional scale anticline, defined by strong VTEM conductors with associated radioactivity along each fold limb.Graphitic pelites have been mapped along both fold limbs, hosting strong radioactivity up to 22,300 cps (RS-125 handheld scintillometer).Mineralized cross-cutting faults have been mapped in the overlying rocks which intersect the uranium-bearing graphitic pelite unit.Historical outcrop sampling at the northwestern graphitic pelite exposure returned assay results of 0.32% U3O8 and 0.30% Cu (SMDI #2095).Unrealized Potential: The targets tested during the summer 2024 program represent only a small fraction of the dozens on the ground and the Company is working with its option partners to prioritize follow ups for additional geophysics and drill programs to further test these promising areas.Davidson River Project - Flagship ProjectIn 2023, the Company expanded its flagship Davidson River project in the southwest corner of the Basin to cover more than 37,700 hectares. Standard Uranium plans to follow up on prospective drilling results from 2022 and test brand new high-priority targets akin to the neighboring JR Zone discovery within the new southeast claim blocks.The summer 2022 program revealed the best intersections of prospective alteration and structure to date along the Bronco and Thunderbird trends, including wide graphitic structural zones on Bronco and oxidized alteration on Thunderbird, in addition to elevated radioactivity and dravite alteration.Planned 2025 drilling will follow up on the most prospective basement structures and alteration zones intersected to date and begin testing new target areas within recently staked claim blocks.Data-driven machine learning techniques will contribute to drill targeting at Davidson River through anomaly detection and mapping of EM data, in addition to anomaly matching based on the footprints of known world-class uranium deposits in the area including the Arrow and Triple-R deposits. The machine learning techniques will also be applied to the Company's internal drilling and geochemical databases.Several kilometres of graphitic conductors remain to be tested at Davidson River, with Davidson River still containing massive blue-sky potential for high-grade discovery akin to the Arrow Deposit on the neighbouring Rook I project owned and operated by NexGen Energy Ltd.Harrison Project - Available for OptionSize & Location: Two mineral claims totalling 1,750 ha, located 22 km SSE of the Shea Creek uranium deposits and approximately 30 km SE of the past producing Cluff Lake uranium mine.Geophysical/Geological Signatures: Electromagnetic ("EM") surveys conducted in 2006-2007 outlined multiple EM zones across the project. Harrison covers approximately 6.8 km of a NW-SE conductor trends coincident with a prominent magnetic low. The trend is crosscut by several interpreted fault zones, including 4.9 km of the major Harrison fault.Prospectivity Model: The project has never been drilled and provides the Company with additional exploration exposure in the southwest Athabasca uranium district. The Company believes the newly acquired Harrison project is prospective for the discovery of high-grade* unconformity-related uranium mineralization.Stock Option and RSU GrantsThe Company also announces that, pursuant to its Omnibus Incentive Plan, it has granted stock options (the "Options") to certain directors, management, and consultants of the Company to purchase an aggregate of 367,500 common shares of the Company at the price of $0.10 per common share until October 31, 2029. Vesting of the stock options shall be as follows: 20% of the Options shall vest immediately, with a further 20% of the Options vesting every three months thereafter.In addition to the Options, the Company has also granted 1,325,000 restricted share units (the "RSUs") to certain directors and senior officers of the Company. The RSUs entitle the holder to receive one common share, the cash equivalent or a combination thereof, on the vesting date of October 31, 2025.*The Company considers uranium mineralization with concentrations greater than 1.0 wt% U3O8 to be "high-grade".** The Company considers radioactivity readings greater than 300 counts per second (cps) to be "anomalous".***Natural gamma radiation in outcrop reported in this news release was measured in counts per second (cps) using a handheld RS-125 super-spectrometer and a downhole Reflex EZ-Gamma probe. Readers are cautioned that scintillometer and gamma probe readings are not uniformly or directly related to uranium grades of the rock sample measured and should be treated only as a preliminary indication of the presence of radioactive minerals.The scientific and technical information contained in this news release has been reviewed, verified, and approved by Sean Hillacre, P.Geo., President and VP Exploration of the Company and a "qualified person" as defined in NI 43-101.Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company's future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects.About Standard Uranium (TSXV: STND)We find the fuel to power a clean energy futureStandard Uranium is a uranium exploration company and emerging project generator poised for discovery in the world's richest uranium district. The Company holds interest in over 233,455 acres (94,476 hectares) in the world-class Athabasca Basin in Saskatchewan, Canada. Since its establishment, Standard Uranium has focused on the identification, acquisition, and exploration of Athabasca-style uranium targets with a view to discovery and future development.Standard Uranium has successfully completed three joint venture earn in partnerships on their Sun Dog, Canary, and Atlantic projects totaling over $23.8M in work commitments over the next three years from 2024-2027.Standard Uranium's Sun Dog project, in the northwest part of the Athabasca Basin, Saskatchewan, is comprised of nine mineral claims over 19,603 hectares. The Sun Dog project is highly prospective for basement and unconformity hosted uranium deposits yet remains largely untested by sufficient drilling despite its location proximal to uranium discoveries in the area.Standard Uranium's Davidson River Project, in the southwest part of the Athabasca Basin, Saskatchewan, comprises ten mineral claims over 30,737 hectares. Davidson River is highly prospective for basement-hosted uranium deposits due to its location along trend from recent high-grade uranium discoveries. However, owing to the large project size with multiple targets, it remains broadly under-tested by drilling. Recent intersections of wide, structurally deformed and strongly altered shear zones provide significant confidence in the exploration model and future success is expected.Standard Uranium's eastern Athabasca projects comprise over 42,384 hectares of prospective land holdings. The eastern basin projects are highly prospective for unconformity related and/or basement hosted uranium deposits based on historical uranium occurrences, recently identified geophysical anomalies, and location along trend from several high-grade uranium discoveries.For further information contact:Jon Bey, Chief Executive Officer, and ChairmanSuite 918, 1030 West Georgia StreetVancouver, British Columbia, V6E 2Y3Tel: 1 (306) 850-6699E-mail: info@standarduranium.caCautionary Statement Regarding Forward-Looking StatementsThis news release contains "forward-looking statements" or "forward-looking information" (collectively, "forward-looking statements") within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. Forward-looking statements include, but are not limited to, statements regarding: the timing and content of upcoming work programs; geological interpretations; timing of the Company's exploration programs; and estimates of market conditions. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Certain important factors that could cause actual results, performance or achievements to differ materially from those in the forward-looking statements are highlighted in the "Risks and Uncertainties" in the Company's management discussion and analysis for the fiscal year ended April 30, 2024.Forward-looking statements are based upon a number of estimates and assumptions that, while considered reasonable by the Company at this time, are inherently subject to significant business, economic and competitive uncertainties and contingencies that may cause the Company's actual financial results, performance, or achievements to be materially different from those expressed or implied herein. Some of the material factors or assumptions used to develop forward-looking statements include, without limitation: that the transaction with the Optionee will proceed as planned; the future price of uranium; anticipated costs and the Company's ability to raise additional capital if and when necessary; volatility in the market price of the Company's securities; future sales of the Company's securities; the Company's ability to carry on exploration and development activities; the success of exploration, development and operations activities; the timing and results of drilling programs; the discovery of mineral resources on the Company's mineral properties; the costs of operating and exploration expenditures; the presence of laws and regulations that may impose restrictions on mining; employee relations; relationships with and claims by local communities and indigenous populations; availability of increasing costs associated with mining inputs and labour; the speculative nature of mineral exploration and development (including the risks of obtaining necessary licenses, permits and approvals from government authorities); uncertainties related to title to mineral properties; assessments by taxation authorities; fluctuations in general macroeconomic conditions. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Any forward-looking statements and the assumptions made with respect thereto are made as of the date of this news release and, accordingly, are subject to change after such date. The Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228449 Copyright 2024 ACN Newswire via SeaPRwire.com.
More
傳特朗普若當選 將要求內塔尼亞胡在明年1月前結束以巴衝突 News

傳特朗普若當選 將要求內塔尼亞胡在明年1月前結束以巴衝突

(SeaPRwire) - 據《以色列時報》報導,前總統唐納·川普據稱要求以色列總理班傑明·內塔尼亞胡在 2024 年 1 月 20 日他宣誓就職之前結束以巴衝突。以色列媒體援引知情人士消息稱,川普是在今年 7 月內塔尼亞胡到佛羅里達州棕櫚灘的 Mar-a-Lago 拜訪他時,向內塔尼亞胡傳達了這個訊息。雖然川普一直表達了結束自 2023 年 10 月 7 日以來持續的戰爭的願望,但要求的時限先前並未被公開。川普在競選活動中並沒有廣泛談論以巴衝突,但一直表達了支持以色列攻擊伊朗核設施的立場。「那是你要打擊的東西,」川普在北卡羅來納州費耶特維爾的集會上說。拜登-賀錦麗政府一直以來對以色列持支持立場,但白宮已公開批評以色列國防軍(IDF)最近的軍事行動。本月早些時候,拜登總統在以色列入侵黎巴嫩之前不久,要求停火。在 CNN 上週舉辦的市民大會上,賀錦麗避開了安德森·庫珀關於她是否比共和黨對手更支持以色列的問題。「我相信唐納·川普很危險,」賀錦麗說,沒有回答這個問題。「我相信當美國總統對他的將軍們說,因為他是三軍統帥,這些對話,我猜想,其中許多是在橢圓形辦公室進行的,如果美國總統,三軍統帥,對他的將軍們說,『為什麼你們不能更像希特勒的將軍們?』安德森,拜託。」 Digital 已聯繫川普競選團隊尋求評論。本文由第三方廠商內容提供者提供。SeaPRwire (https://www.seaprwire.com/)對此不作任何保證或陳述。 分類: 頭條新聞,日常新聞 SeaPRwire為公司和機構提供全球新聞稿發佈,覆蓋超過6,500個媒體庫、86,000名編輯和記者,以及350萬以上終端桌面和手機App。SeaPRwire支持英、日、德、韓、法、俄、印尼、馬來、越南、中文等多種語言新聞稿發佈。
More

致豐集團旗下 Deltrix與深圳市海梁科技達成深度戰略合作 ,共拓新能源國際市場

EQS 新聞 via SEAPRWire.com / 2024-10-31 / 18:18 UTC+8 致豐集團旗下 Deltrix與深圳市海梁科技達成深度戰略合作 共拓新能源國際市場 [香港 - 2024年10月31日] 致豐工業電子集團有限公司(“致豐集團”或“集團”,股份代號:1710.HK)宣佈集團旗下的 Deltrix Limited 與深圳市海梁科技有限公司在致豐南沙製造總部正式簽署戰略伙伴合作協議,本次合作在新能源領域引發了廣泛關注,被視為行業內的一次重要戰略里程碑。 依據合作協議,雙方將在新能源、新能源汽車産品及應用創新領域內就光儲直柔超級充電站和綜合解决方案進行合作,以共同推動全球新能源産業業務發展,包括但不限於在中國大陸、中國香港、中亞、新加坡、印尼、馬來西亞、中東等多個國家和地區的市場展開全面合作,重點聚焦於光儲直柔超級充電站産品及綜合解决方案的研發、推廣與應用。合作初期的重點項目涵蓋中亞地區光儲直柔充電站建設與運營、香港電動的士之家充電場站建設與運營,以及在國內建設光儲充樣板間等多個項目。合作模式上,雙方依據不同項目的具體需求,合理配置並投入相應的資源和能力,共同打造具有市場影響力的雙品牌項目。 在技術研發層面,雙方均展現出對前沿技術探索的堅定决心。Deltrix一直致力於新能源技術研發的投入和創新,其研發團隊在儲能技術、智能充電技術等方面取得了一系列成果。海梁科技則在充儲直柔技術方面有著深入研究,其研發的新型儲能材料有望進一步提升儲能系統的性能。通過雙方的技術協同,預計將在未來短期內推出一系列更具競爭力的光儲直柔超級充電站産品及綜合解决方案,滿足市場對新能源基礎設施不斷升級的要求。 在市場拓展方面,雙方憑藉各自在不同地區和國家的市場優勢以及一帶一路政策的有力支持,制定了詳細的市場拓展計劃。Deltrix在全球多個地區擁有廣泛的業務網絡,這將為合作項目的市場拓展提供有力支撑。預計在未來三年內,雙方合作的光儲直柔超級充電站産品及綜合解决方案預計將在大亞洲市場實現大規模應用和推廣。其中,中國香港地區將會成為雙方合作起點的重要市場增長點。此外,中亞地區也是雙方未來合作的主戰場,Deltrix在中亞已取得較佳的市場開拓成果,雙方將借助中亞市場打造示範合作項目,再逐步拓展到全球其它地區。本次合作除了會給雙方帶來可觀的經濟效益,還會顯著提升雙方的品牌知名度和國際影響力。 在産業協同方面,雙方的合作將對新能源産業鏈産生深遠影響。Deltrix在産業鏈上下游擁有豐富的資源和整合能力,在充電樁生産環節具有規模優勢,海梁科技在光儲直柔系統集成方面具有技術優勢. 雙方的戰略合作可以實現資源的優化配置,降低生産成本,提高生産效率,實現零部件採購的協同,减少中間環節,提高供應鏈效率。同時,還將促進新能源産業技術標準的統一和規範,推動整個新能源産業朝著更加有序、高效的方向發展,為全球新能源産業的升級和進步貢獻重要力量。 Deltrix 與海梁科技的合作是新能源領域的一次重要戰略布局,雙方將擕手共進,抓住新能源産業發展的歷史機遇,為全球新能源産業的發展注入新的活力,共同開創一個更加綠色、可持續的未來。 致豐集團主席黃思齊先生寄語:「值此致豐與海梁成功簽署合作協議之際,我對雙方的合作充滿信心。此次合作堪稱強強聯合,通過新能源業務,我們將實現互惠互利。致豐擁有豐富的資源,在生産和廠房技術方面實力雄厚,並且在海外市場擁有廣泛的資源和市場能力。海梁科技在研發技術和系統設計方面表現卓越,特別是在光伏和儲能領域有著獨特的技術專長。雙方的企業文化非常接近,這使得我們成為絕佳的生意夥伴。在新能源和 EMS 方面,我堅信我們擁有巨大的合作空間。我們將擕手共進,進一步提升雙方的業務層次,共同開創合作共贏的新局面,為行業發展注入新的活力。」 海梁科技董事長胡劍平先生寄語:「在海梁科技與致豐達成合作協議這一令人振奮的時刻,我深感欣喜。致豐作為一家擁有 40 多年工業製造積累的香港上市公司,其深厚的底蘊令人欽佩。在新能源領域的製造更是處於行業領先水平,這為我們的合作奠定了堅實的基礎。海梁科技在應用場景方面獨具優勢,擁有三十多年交通、出行、城市電動化解决方案的經驗。我們與致豐在業務上具有很強的互補性,致豐主要提供製造、産品和解决方案,而我們側重於應用場景。我們非常看重致豐的能力和平台,雙方強強聯合,借助致豐的平台以及海梁科技股東德國大眾集團商用車公司的資源優勢,擕手出海。我們將整合産業鏈、優秀的軟硬件資源,包括光伏、儲能、充電、智能微電網等,真正把中國的新能源經驗推向海外,為全球新能源産業的發展貢獻我們的力量。」 關於致豐集團 致豐集團為香港先進工業電子零件及産品製造及銷售企業,並為香港電子工業供應商中首間企業獲工業4.01i級的工業4.0成熟度認證證書,擁有近40年行業經驗。集團的主要產品包括:智能充電樁、機電産品及開關電源等,廣泛應用於智慧城市系統、醫療保健及再生能源領域。集團並建立良好的聲譽,成為眾多國際知名品牌信賴的供應商。客戶主要來自歐美,部分來自東南亞及中國。其中,集團因應全球發展智慧經濟,於2017年起與合作夥伴研發自有電動車充電解决方案Deltrix,並在歐洲市場推出。 如欲查詢更多資訊,請聯絡: 投資者關係: Skye Shum - 投資者關係經理 傳媒查詢: DLK Advisory pr@dlkadvisory.com 文件: 致豐集團旗下 Deltrix與深圳市海梁科技達成深度戰略合作 共拓新能源國際市場 2024-10-31 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php
More
Mazda Launches Redesigned Corporate Website JCN Newswire

Mazda Launches Redesigned Corporate Website

HIROSHIMA, Japan, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Mazda Motor Corporation today launched a redesigned corporate website. Amid growing awareness and interest in sustainability, the company redesigned its website to provide stakeholders visiting the corporate website with more timely and user-friendly access to financial and non-financial data as well as information about initiatives set to enhance both corporate and social value.Within the corporate website, it also set up MAZDA MIRAI BASE, a new owned-media platform filled with videos and photos, to share stories about Mazda’s work to build a better future.Mazda Motor Corporation Website URL:Japanese - www.mazda.com/ja/English - www.mazda.com/en/MAZDA MIRAI BASE URL:Japanese - www.mazda.com/ja/mazda-mirai-base/English - www.mazda.com/en/mazda-mirai-base/Key ImprovementsMazda’s website that presents the company’s worldview more clearly offering enhanced usabilityTo help our stakeholders quickly find information they need and access a broader range of corporate data, Mazda redesigned its website structure and reorganized the information posted. In addition, the content was optimized to convey Mazda’s corporate philosophy, established last year, and value creation approach, arranging these in a restructured corporate website that articulates our worldview seeking to create a vibrant future.New MAZDA MIRAI BASE platformThis new owned-media platform MAZDA MIRAI BASE has been created to share Mazda’s aspirations and initiatives for realizing its corporate philosophy and 2030 Vision. Working from the concept of a “media platform that connects with partners to create an exciting future,” MAZDA MIRAI BASE distributes articles, video and photos to tell stories about ”creating the joy of living” found in manufacturing safe and reliable automobiles, manufacturing sustainably, and creating moving experiences.Mazda will continue to pursue the ‘Joy of Driving’ under its core value “Human Centric,” and aim to deliver the ‘Joy of Living’ by creating moving experiences in customers' daily lives.Reference:Mazda’s Corporate Philosophy- Japanese https://www.mazda.com/ja/about/philosophy/- English https://www.mazda.com/en/about/philosophy/ Copyright 2024 JCN Newswire via SeaPRwire.com.
More
NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents JCN Newswire

NTT and Toyota Motor Corporation agree to joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents

Toyota City, Japan, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Today, Toyota Motor Corporation (hereafter, Toyota) and Nippon Telegraph and Telephone Corporation (hereafter, NTT) have agreed to a joint initiative in the field of mobility and AI/telecommunications with the aim of realizing a society with zero traffic accidents.Through their previous collaborations, the two companies have confirmed that they share common values, such as contributing to society through technological and industrial development, a people-centered approach, and global contributions that start in Japan. This time, they will further deepen their collaboration with the aim of achieving a "society with zero traffic accidents" as the first step towards realizing a prosperous mobility society where safety and freedom are in harmony.In order to achieve a society with zero traffic accidents, it is necessary to take an infrastructure-cooperative approach that constantly connects people, mobility and infrastructure, in addition to the advancement of driving support technology based on data-driven technology in cars and the development of future automated driving technology.To achieve both of these things, Toyota is developing Software Defined Vehicles (SDV) with safety and security as the top priority. Alongside the evolution of SDV, it will become more important to build infrastructure such as a high-speed, high-quality communication infrastructure, an AI infrastructure that can collect and intelligently process vast amounts of information, and a computing infrastructure.In this collaboration, NTT, whose strengths lie in the telecommunications, and Toyota will jointly build a "Mobility AI Platform" that combines a seamless communications infrastructure with AI and computing platforms that can intelligently process large amounts of data. By doing so, they aim to connect people, mobility, and infrastructure to realize a safe, secure, and sustainable mobility society with no traffic accidents.Details of the joint initiativeWe will jointly develop and operate the "Mobility AI Platform" and use it in our efforts(1) to achieve a society with zero traffic accidents. The Mobility AI Platform is made up of multiple elements(2).The Mobility AI Platform aims to standardize the mobility field, and we envision that it will be used not only by the two companies, but also by a wide range of industry, government, and academic partners who share the goal of realizing a society with zero traffic accidents.Through this initiative, the two companies expect to invest a total of 500 billion yen by 2030. Starting in 2025, they will begin development of the Mobility AI Platform, and from around 2028 under the three-pronged infrastructure, they will begin social implementation and collaboration with various partners, aiming for widespread adoption from 2030 onwards.(1) Main initiatives aimed at achieving a society with zero traffic accidents- Three-pronged infrastructure collaboration" to prevent collisions at blind intersections, etc.- Development of advanced driving support/future automated driving systems" that are data-driven, with AI learning on its own based on large amounts of driving data(2) Elements that make up the mobility AI platform1. Distributed computing platform (data center)Computing resources (data centers) for analyzing and processing vast amounts of data using AI are installed in distributed locations, utilizing IOWN's optical communication technology. By locating them in areas rich in renewable energy, we can achieve local production for local consumption of electricity, and by achieving high power efficiency in the coordination and processing of distributed computing resources and AI, we can promote the greening of the vast amounts of electricity needed for data analysis and processing.2. Intelligent communication infrastructureA system is being built to coordinate human mobility infrastructure through seamless communication that is suitable for various traffic environments and conditions in urban areas, rural areas, and suburbs. In addition to being highly reliable, it also achieves low-latency communication for large volumes of data.3. AI infrastructureA platform that achieves mobility AI that learns and infers from various data from human mobility infrastructure, based on a "distributed computing infrastructure (data center)" and "intelligent communication infrastructure". Copyright 2024 JCN Newswire via SeaPRwire.com.
More
All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024 JCN Newswire

All-New Triton Wins Golden Award at VMARK Vietnam Design Awards 2024

TOKYO, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Mitsubishi Motors Corporation (hereafter, Mitsubishi Motors) announced that the all-new Triton has been selected as a golden award winner at the VMARK Vietnam Design Awards 2024 in the Best Transportation Design category. This marks the second time that Mitsubishi Motors has won the award, after the Xforce topped the same category in 2023.Established in 2018, the VMARK Vietnam Design Awards is organized by the VDAS Design Association based in Ho Chi Minh City. This year, a jury of 42 internationally renowned design practitioners evaluated design projects from Vietnam and around the world, and each entry was evaluated against the five criteria of innovativeness, eco-friendliness, identity, functionality, and community. The most outstanding designs received the golden award, and this year, 19 projects were selected as gold award winners out of a total of 700 entries.The Triton is Mitsubishi Motors' one-ton pickup truck that traces its roots back to the Forte originally released in 1978. In the 45 years since, this global strategic vehicle from Mitsubishi Motors has sold a cumulative total of approximately 5.7 million units in approximately 150 countries spanning five generations of models. Developed under the product concept of "Power for Adventure," the all-new Triton features a complete overhaul of everything from the interior and exterior design to the chassis, ladder frame and engine, and more. It was first launched in Thailand – where its production site is located – in July 2023 and introduced in Japan in February 2024. The all-new Triton is being rolled out sequentially in 100 countries worldwide.In attending the VMARK Vietnam Design Award 2024 ceremony, Kazuhiro Watanabe, Division General Manager of Sales & Marketing Division, Mitsubishi Motors Vietnam Co., Ltd., commented: “This award is a testament to our 30-year journey of 'Drive ahead together for everyday Adventure' in Vietnam. The all-new Triton embodies this commitment by delivering exceptional quality, innovation, and a driving experience that resonates with the adventurous spirit of the Vietnamese people.”Norihiko Yoshimine, Product Design Director, Mitsubishi Motors, who designed the Triton, cheerfully commented, “The Triton expresses the majestic aura that is distinctively Mitsubishi, possessing both robustness and agility in addition to the toughness and sheer power expected of a pickup truck. Following in the footsteps of the award for the Xforce last year, I am deeply honored that the all-new Triton has earned such high recognition at the VMARK Vietnam Design Awards this year. This award will provide a boost, but we will also continue doing our utmost to promote the Triton’s appeal to even more customers in Vietnam.”VMARK Vietnam Design Awards 2024 Awards Page (only available in English and Vietnamese) https://www.vietnamdesignweek.org/vmark-vietnam-design-week-2024About Mitsubishi MotorsMitsubishi Motors Corporation (TSE:7211) — a member of the Alliance with Renault and Nissan — is a global automobile company based in Tokyo, Japan, which has about 28,000 employees and a global footprint with production facilities in Japan and the ASEAN region. Mitsubishi Motors has a competitive edge in SUVs, pickup trucks and plug-in hybrid electric vehicles, and appeals to ambitious drivers willing to challenge convention and embrace innovation. Since the production of our first vehicle more than a century ago, Mitsubishi Motors has been a leader in electrification — launched the i-MiEV, the world’s first mass-produced electric vehicle in 2009, followed by the Outlander PHEV, the world’s first plug-in hybrid electric SUV in 2013. With a target of increasing the sales ratio of electrified vehicles to 100% by 2035, Mitsubishi Motors will deliver models that embody Mitsubishi Motors-ness and contribute to the realization of a carbon-neutral society.For more information on Mitsubishi Motors, please visit the company's website athttps://www.mitsubishi-motors.com/en/ Copyright 2024 JCN Newswire via SeaPRwire.com.
More
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference JCN Newswire

Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference

TOKYO and CAMBRIDGE, Mass., Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings for lecanemab-irmb (U.S. brand name: LEQEMBI®), an anti-amyloid beta (Aβ) protofibril* antibody for the treatment of early Alzheimer’s disease (AD), were presented at the Clinical Trials for Alzheimer's Disease Conference (CTAD), held in Madrid, Spain, and virtually.Benefits of Continued Treatment with Lecanemab for People with Early ADIn July 2024 at the Alzheimer's Association International Conference (AAIC) 2024, results from the open-label long-term extension study (OLE) following the core study of the lecanemab Phase 3 Clarity AD study were presented, showing that the mean change from baseline in CDR-SB (global cognitive and functional scale) in the lecanemab treated group relative to the placebo group was -0.45 at 18 months, and at 36 months, this expanded to -0.95 compared to a prespecified natural history** cohort of AD. There was a 30% reduction in the relative risk of progressing to the next disease stage In addition, the tau PET substudy of the lecanemab Phase 3 Clarity AD clinical study showed that with three (3) years of continuous treatment with lecanemab, 59% of patients with no or low tau accumulation in the brain (no tau/low tau) at baseline showed improvement or no decline, and 51% showed improvement from baseline on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) global cognitive and functional scale.1Clarity AD data presented at CTAD expand on these initial results to include additional measurements resulting from three (3) years of continuous lecanemab treatment in patients with low levels of amyloid accumulation in the brain at baseline (less than 60 Centiloids: low amyloid). These data show that 46% of patients improved or had no decline, and 33% showed improvement from baseline on the CDR-SB. On the ADAS-Cog14 measurement scale, 46% of patients showed improvement or no decline and 43% showed improvement. On the ADCS MCI-ADL, 51% of patients showed improvement or no decline and 48% showed improvement. These results – from no tau/low tau population and low amyloid populations – suggest that earlier initiation of lecanemab treatment may have a positive impact on disease progression of early AD patients and may provide continued benefits to patients with early AD over the long term.2No new safety findings were observed with continued lecanemab treatment over three (3) years. Most amyloid-related imaging abnormalities (ARIA) occurred in the first six (6) months of treatment. After the first six (6) months, ARIA rates were low and similar to ARIA rates on placebo during the placebo- controlled period. With regards to the incidence of ARIA by ApoEε4 status during the continuous treatment, the incidence was higher in ApoE4 homozygotes than in heterozygotes or non-carriers, but rates of new ARIA were decreased after the completion of the 18 months core study as treatment continued, regardless of ApoEε4 status.2Correlation between Protofibrils and Biomarkers for Neurodegenerative Disease in the AD Brain Dual-acting lecanemab is the only early AD treatment available to support neuronal function by clearing the highly toxic protofibrils that continue to cause neuronal injury and death even after plaques have been cleared from the brain. Protofibrils accumulate early in the AD brain and lead to nerve cell function loss, abnormal nerve processes, inflammation, and memory loss. In non-clinical studies, antibodies against protofibrils prevented protofibril-mediated neuronal dysfunction and memory loss.Accurately quantifying the amount of protofibrils in human cerebrospinal fluid (CSF) has been challenging due to their low concentration. As such, a new measurement method was developed by researchers at Eisai to accurately quantify protofibrils in CSF.Utilizing this new method of measurement, the amount of protofibrils in AD CSF correlated more strongly with neurodegenerative disease biomarkers (CSF total tau and neurogranin) than with CSF Aβ42, a biomarker associated with Aβ plaques accumulation, indicating that protofibrils are closely related to synaptic dysfunction. Furthermore, it was observed that protofibrils, unlike plaques, are diffusible. These results suggest that protofibrils induce synaptic dysfunction, playing an important role in neurodegeneration in AD brains.3Lecanemab Treatment for Early AD: Insights from Long-Term U.S. Clinical StudiesDr. Marwan Noel Sabbagh, Moreno Family Chair for Alzheimer's Research and Vice Chairman for Research and Professor, Department of Neurology, Barrow Neurological Institute, presented outcomes of an analysis of the use of lecanemab treatment between January 6, 2023, and July 30, 2024, based on payment claims data from the Komodo Research Database, a medical database in the U.S. In the U.S., lecanemab is used in accordance with the US FDA-approved indication, dosing, and monitoring guidelines. The analysis found that access to lecanemab treatment is expanding and highlighted opportunities to improve access in rural areas and educational outreach for underserved populations.4Dr. David Watson of the Alzheimer's Research and Treatment Center reported on patients who continued to receive lecanemab treatment following the Phase II Study 201 and Phase III Clarity AD study. A total of 136 patients participated in both studies at this center, and 66 patients chose to continue lecanemab therapy, with 13 patients receiving treatment for more than five (5) years and 40 patients receiving treatment for more than three (3) years. More than half of the patients (15/24) who continued treatment with lecanemab for more than three (3) years after the core phase remained in their initial stage of disease. Further, in a survey of 11 patients (or their caregivers) who received lecanemab treatment for more than five (5) years, all patients responded that they were “very satisfied” or “satisfied” with lecanemab treatment. In addition, between 45% and 73% of patients responded that lecanemab treatment made them feel more positive about their daily life, social activities, memory, etc. "frequently" or "very often."5No new long-term safety findings were observed in these multi-year studies.5Progress in the AHEAD 3-45 Study: Improving Screening Eligibility Using Blood Biomarkers and Completing Patient EnrollmentAHEAD 3-45 is a Phase 3 clinical study for individuals with preclinical AD, meaning they are clinically unimpaired but have intermediate or elevated levels of amyloid in their brains. In the study, blood tests, cognitive function tests (PACC-5***), amyloid PET, MRI, and tau PET were used for screening. Based on the amount of Aβ accumulation in the brain as determined by amyloid PET, subjects were assigned to two (2) trials with different dose settings: the A3 trial, for those with borderline Aβ levels in the brain, and the A45 trial, for those with positive Aβ levels in the brain.6Screening with blood biomarker tests was important to improve eligibility for amyloid PET testing in subjects without cognitive impairment. Using plasma Aβ42/40 ratio and p-tau217/tau217 ratio in theinitial screening reduced screening failure on amyloid PET from more than 70% to less than 30%. In particular, plasma p-tau217 was shown to correlate with amyloid PET, supporting its role as a useful blood biomarker to identify elevated amyloid in the brain.6Enrollment for the AHEAD 3-45 study was completed in October 2024.Lifetime Achievement Award Presented to Professor LannfeltProfessor Emeritus Lars Lannfelt of Uppsala University received the CTAD Lifetime Achievement Award in recognition of his pioneering work in scientific discovery and drug development in AD. As part of this award ceremony, he delivered a keynote speech outlining the discovery of the arctic mutation in familial AD, its application to therapeutic strategies targeting protofibrils for AD treatment, and the development of lecanemab.Eisai serves as the lead for lecanemab’s development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision- making authority.*Protofibrils are believed to contribute to the brain injury that occurs with AD and are considered to be the most toxic form of Aβ, having a primary role in the cognitive decline of this progressive, debilitating condition.7 Protofibrils cause injury to neurons in the brain which, in turn, can negatively impact cognitive function through multiple mechanisms, not only increasing the development of insoluble Aβ plaques but also increasing direct damage to brain cell membranes and the connections that transmit signals between nerve cells or nerve cells and other cells. It is believed the reduction of protofibrils may prevent the progression of AD by reducing damage to neurons in the brain and cognitive dysfunction.8**ADNI is a clinical research project launched in 2005 to develop methods to predict the onset of AD and to confirm the effectiveness of treatments. The ADNI observational cohort was pre-specified and used during the design of Clarity AD. The cohort represents the exact population of those in Clarity AD study; matched ADNI participants show similar degree of decline to placebo group out to 18 months.***PACC-5 is a composite measure that provides a highly sensitive measure of changes in cognitive function in individuals with preclinical AD.About lecanemab (LEQEMBI®)Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab is approved in the U.S., Japan, China, South Korea, Hong Kong, Israel, the United Arab Emirates and Great Britain. Eisai has also submitted applications for approval of lecanemab in 10 countries and regions, including the European Union (EU).LEQEMBI’s approvals in these countries were based on Phase 3 data from Eisai’s, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo.9,10 The mean CDR- SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P
More
Beginner’s Guide to Travel Credit Cards ACN Newswire

Beginner’s Guide to Travel Credit Cards

SINGAPORE, Oct 31, 2024 - (ACN Newswire via SeaPRwire.com) - Whether you're a frequent business traveller who's always on the go or a world explorer looking for your next adventure, a travel credit card can be a great way to make the best of your trips. The right travel credit card can enhance your travel experiences by offering opportunities to earn rewards, redeem rewards on travel expenses, access discounts and deals, and get perks and benefits like lounge access and travel insurance. Learn all about travel credit cards, what they can do for you and how to choose the right one in our guide below.What is a travel credit card?You may have heard of credit cards that offer discounts and savings on fuel, groceries or shopping. A travel credit card is a type of credit card that offers perks and rewards that make travel smooth and convenient. While the exact reward programs differ from one card to the next, what most miles credit cards have in common is that they grant users benefits and redemption opportunities specifically linked to travel.A travel credit card is a great way to turn everyday spending into travel rewards. Generally, a miles credit card or travel card will let you earn points, miles, or cashback on purchases, which you can redeem for travel-related expenses like flight tickets, hotel stays, car rentals, and more. Over time, savvy cardmembers may accumulate enough rewards to cover the full cost of a small vacation. Many travel credit cards also include benefits like complimentary lounge access, travel insurance, and exclusive discounts with partner airlines and hotels.Pros and Cons of a Travel Credit CardProsEarning points and miles: Your miles credit card helps you earn rewards on eligible purchases. If you use your credit card regularly for eligible purchases, your points or miles can add up quickly and bring you significant savings on your next trip.Sign-up bonuses: In addition to regular rewards, your card may offer a welcome bonus that lets you earn a significant number of points/miles if you meet certain spending criteria. These bonuses can provide a great boost to your rewards balance right from the start.Access to Airport Lounges: Your travel credit card may also include complimentary access to airport lounges, allowing you to enjoy a more relaxed travel experience with amenities like refreshments and comfortable seating before your flight.ConsHigh annual fees: Travel credit cards with good benefits may carry higher annual fees than regular cards. You'll need to review the costs and benefits associated with your credit card to decide if the travel benefits are worth the annual fee.Complex rewards systems: Rewards programs are only useful if you know how to use them well. It might take some time and effort to fully understand how to maximize your rewards.How to Choose a Travel Credit CardWhen choosing a travel or miles credit card in Singapore, consider your travel habits and preferences. Start by considering how often you travel. A card with a high fee may be worth it for frequent fliers, but if you only take one or two trips a year, seek out a card with a low or no annual fee with points that don't expire. You'll need to consider what benefits matter to you. Do you value lounge access, or is travel insurance more important? Choose a card that offers benefits that match your needs. Lastly, look for a rewards program that fits in with your lifestyle. If you spend a lot on dining and shopping, look for a card that offers higher rewards in those categories. Additionally, carefully review the points/redemption process before you apply for a travel credit card. A complex redemption process can be off-putting especially if there are many limits placed on redemption.Notice:Opinions, analyses, reviews, or recommendations expressed in this article are those of the select editorial staff's alone, and have not been reviewed, approved, or otherwise endorsed by any third party.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2024 ACN Newswire via SeaPRwire.com.
More
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD) JCN Newswire

Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD)

TOKYO, Oct 31, 2024 - (JCN Newswire via SeaPRwire.com) - Eisai Co. Ltd announced today that the latest findings on anti-MTBR (microtubule binding region) tau antibody E2814 were presented at the 17th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Madrid, Spain, and virtually. Eisai also announced initiation of a Phase II study (Study 202) on E2814 for sporadic early Alzheimer’s Disease (AD).Impact of the anti-MTBR tau antibody E2814 on tau pathology biomarkers in Dominantly Inherited Alzheimer’s Disease (DIAD)E2814 is an investigational anti-MTBR tau antibody designed to target the MTBR of tau. In AD patients, neurofibrillary tangles (NFT) are a pathological hallmark, and they are believed to spread through synaptically connected pathways in the brain, forming the tau propagation hypothesis. It is thought that tau propagation is drivenby the specific tau species containing MTBR, tau seeds that spread tau pathology to different brain regions important for cognition and function.Eisai conducted a Phase I/II clinical study (Study 103, NCT04971733; 7 participants) of the anti-MTBR tau antibody E2814 in patients with Dominantly Inherited Alzheimer’s Disease (DIAD) beginning in June 2021. This study aimed to evaluate the safety and tolerability of E2814 in DIAD patients, with a primary objective of assessing the target engagement of E2814 with MTBR-tau species in their cerebrospinal fluid (CSF). In addition, pharmacodynamicevaluation was performed using multiple biomarkers related to AD tau pathology. In the study, DIAD patients withclinical symptoms were administered E2814 for 12 to 24 months. Data from the Dominantly Inherited Alzheimer Network Observational Study (DIAN-obs), an observational cohort of DIAD, were used as references to evaluate biomarkers changes in E2814 treatment.Compared to the reference data from DIAN-obs, patients who received E2814 showed approximately 75% and 50% reductions of CSF MTBR-tau243 and p-tau217, respectively, reflecting tau pathophysiology. Additionally, braintau accumulation observed by tau PET was stabilized or trended toward decrease in DIAD subjects administered E2814. These results suggest that E2814 inhibited tau propagation and suppressed the accumulation of tau aggregates in brains of people living with DIAD. This will be further investigated in the ongoing Phase II/III Tau NexGen study (NCT05269394) with DIAD patients and the Phase II 202 study (NCT06602258) with sporadic early Alzheimer’s disease (AD) patients.Initiation of Phase II clinical study (Study 202)In September 2024, Eisai initiated a Phase II clinical study (Study 202) for individuals with early AD in the United States. The study is also scheduled to be conducted in Japan in the future. This study is a placebo- controlled,double-blind, parallel-group, dose exploration study, evaluating the safety, tolerability, and biomarker efficacy of E2814 in people living with early AD receiving lecanemab as a backbone anti-Aβ therapy.Eisai positions neurology as a key therapeutic area, and it will continue to create innovation in the development of novel medicines based on cutting-edge neurology research as it seeks to contribute further to improving the benefits of affected individuals and their families in diseases with high unmet needs, such as dementia including AD.This release discusses investigational uses of agents in development and is not intended to convey conclusionsabout efficacy or safety. There is no guarantee that such investigational agents will successfully complete clinical development or gain health authority approval.About E2814An investigational anti-microtubule binding region (MTBR) tau antibody, E2814 is being developed as a disease- modifying agent for tauopathies including sporadic Alzheimer’s disease (AD). Phase I clinical studies are underway. E2814 was discovered as part of the research collaboration between Eisai and University College London. E2814 is designed to prevent the spreading of tau seeds within the brains of affected individuals. In addition, E2814 has been selected as an anti-tautherapy in a Phase II/III Tau NexGen study for the treatment of DIAD, conducted by DIAN-TU led by Washington University School of Medicine in St. Louis, is underway.Biomarkers related to AD tau pathologyAs fluid biomarkers related to AD tau pathology, tau containing the residue 243 (MTBR-tau243) and tau phosphorylated at theresidue 217 (p-tau217) in CSF have been reported.1 In addition, positron emission tomography (tau PET), which specifically detects tau aggregates, is used as an imaging biomarker. These biomarkers are included in the Revised criteria for diagnosis and staging of Alzheimer's disease published by the National Institute on Aging and the Alzheimer's Association (NIA-AA) in June 2024.2(1) Horie K, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease. Nat Med. 2023. 29. 1954-1963(2) Jack Jr. CR, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement. 2024. 20. 5143-5169For further information: Media Inquiries:Eisai Co., Ltd.Public Relations Department TEL: +81 (0)3-3817-5120Eisai Inc. (U.S.) Libby Holman+1-201-753-1945Libby_Holman@Eisai.comEisai Europe, Ltd. (UK, Europe, Australia, New Zealand and Russia) EMEA Communications Department+44 (0) 786 601 1272EMEA-comms@eisai.net Copyright 2024 JCN Newswire via SeaPRwire.com.
More
旅行信用卡初學者指南 ACN Newswire

旅行信用卡初學者指南

新加坡, 2024年10月31日 - (亞太商訊 via SeaPRwire.com) - 無論您是經常出差的商務旅行者,還是尋找下一個冒險的全球探索者,旅行信用卡都可以讓您的旅行更加充實。合適的旅行信用卡不僅可以幫助您賺取獎勵,還可以將獎勵用於旅行開銷,享受折扣和優惠,並獲得諸如貴賓室通道和旅行保險等福利。通過我們的指南,了解旅行信用卡的所有信息、它能為您帶來什麼,以及如何選擇合適的旅行信用卡。什麼是旅行信用卡?您可能聽說過一些信用卡提供燃油、雜貨或購物方面的折扣和優惠。旅行信用卡是一種專門提供與旅行相關的優惠和獎勵的信用卡,使旅行更順暢、更便捷。儘管每種卡的獎勵計劃有所不同,但大多數旅行信用卡的共同點在於,它們為用戶提供特定於旅行的福利和兌換機會。旅行信用卡是將日常消費轉化為旅行獎勵的好方法。一般而言,旅行信用卡或里程卡允許您在消費時賺取積分、里程或返現,並將其用於旅行相關的開銷,如機票、酒店住宿、汽車租賃等。通過長期累積,精明的持卡人甚至可以積攢足夠的獎勵來支付一小次度假旅行的全部費用。許多旅行信用卡還包括免費貴賓室通行、旅行保險和與合作航空公司及酒店的獨家折扣等福利。旅行信用卡的優缺點優點賺取積分和里程:使用里程信用卡可以在符合條件的消費中賺取獎勵。如果您經常使用信用卡進行符合條件的消費,積分或里程將很快累積,為您的下一次旅行帶來顯著節省。開卡獎勵:除了常規獎勵外,您的信用卡還可能提供開卡獎勵。如果您滿足一定的消費條件,便可獲得大量積分或里程。這些獎勵可以從一開始就大大增加您的積分餘額。機場貴賓室通行:您的旅行信用卡可能還包含免費機場貴賓室通行,讓您在飛行前享受更放鬆的旅行體驗,包括飲品、點心和舒適的座椅等設施。缺點高年費:擁有良好福利的旅行信用卡的年費通常高於普通信用卡。您需要權衡信用卡的費用與收益,以決定旅行福利是否值得支付高額年費。複雜的獎勵系統:獎勵計劃只有在您會使用時才有用。可能需要花費一些時間和精力來充分理解如何最大化您的獎勵。如何選擇旅行信用卡在新加坡選擇旅行或里程信用卡時,需考慮您的旅行習慣和偏好。首先,評估您的旅行頻率。對於常常出行的旅客來說,高年費的信用卡可能是值得的,但如果您每年僅旅行一到兩次,最好選擇年費較低或無年費且積分不會過期的卡。還要考慮哪些福利對您更重要。您是否看重貴賓室通行,或認為旅行保險更重要?選擇能夠滿足您需求的信用卡。最後,尋找適合您生活方式的獎勵計劃。如果您在餐飲和購物上花費較多,尋找一張在這些類別中提供更高獎勵的信用卡。此外,在申請旅行信用卡前,仔細查看積分/兌換流程。複雜的兌換流程可能會讓人望而卻步,特別是當兌換受到多種限制時。本文中所表達的意見、分析、評論或建議僅代表特定編輯團隊的個人觀點,未經過任何第三方的審查、批准或其他形式的認可。媒體聯絡:姓名: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.com職位名稱: 經理來源: iQuanti, Inc. Copyright 2024 亞太商訊 via SeaPRwire.com.
More

【新聞稿】中國心連心公佈2024年首三季度業績

EQS 新聞 via SEAPRWire.com / 2024-10-31 / 11:58 UTC+8 新聞稿 (請即時發送) 中國心連心2024年首三季盈利同比大幅增長80% 降本增效、優化資源配置成效顯現 2024年首三季度業績重點: 淨利潤達人民幣20.31億元,同比增長75.8%。 歸屬於母公司擁有人淨利潤達人民幣15.34億元,同比大幅增長80.7%。 基本每股收益為人民幣1.26元,同比增長85.3%。 資產負債率下降至59.4%,財務狀況持續改善。 (2024年10月31日,香港)中國心連心化肥有限公司(「中國心連心」或「本公司」,連同其附屬公司合稱「集團」)(股份代號:01866.HK)宣佈,截至2024年9月30日止九個月(「回顧期」),集團實現收入約174.2億元(人民幣,下同),淨利潤同比增長75.8%至20.31億元,歸屬於母公司擁有人淨利潤同比大幅增長80.7%至15.34億元。 二零二四年前三季度,集團受益於原料價格下滑及生產穩定運行,毛利同比增長5%。通過有效的費用管控,管理費用及財務費用分別下降2%和13%。此外,出售天欣煤業的投資收益約為7.9億元。上述因素帶動集團的淨利潤顯著提升。在此基礎上,集團完成對附屬非全資子公司增資,擴大持股比例至80.18%,歸屬於母公司的淨利潤明顯增長。 在全球經濟逐步復甦的背景下,集團主要產品的市場需求保持穩定,儘管原材料價格波動對產品價格造成一定影響,但集團通過擴大產能和拓展銷售渠道,實現了穩健的業績增長。期內化肥板塊銷售收入佔總收入的60%,化工板塊佔36%,氣體板塊佔2%,醫藥中間體佔2%。 回顧期內,受惠於產能擴大以及生產設備的恢復,集團尿素產品銷量同比增加33%至276.8萬噸。通過加大對高效複合肥及差異化肥料的推廣,複合肥整體毛利率同比提升5個百分點。甲醇需求隨著經濟回暖而有所增長,期內銷量同比提升17%,毛利率同比上升8個百分點。 集團通過靈活調整產能,提高生產效率,進一步滿足下遊製造業的需求。三聚氰胺雖然受到房地產業疲軟的影響,價格下降8%,但通過國際市場的開拓,特別是在土耳其等地的出口增長,銷量同比增加9%。 2024年首三季度,DMF在技術改進和設備穩定運行的支持下,銷量同比增長33%。醫藥中間體板塊方面,集團優化產品結構,加大高附加值產品的銷售佔比,平均售價同比上升18%。 展望未來,中國心連心董事長劉興旭先生表示:第四季度將進入迎峰度冬的需求旺季,在宏觀政策的支持下,原料煤炭價格有望企穩回升,對化肥價格形成有效支撐。隨著環保及產能調控政策的實施,氮肥供給將出現階段性減少,而在冬儲備肥及淡儲採購的支持下,預計化肥價格將逐步穩定。集團將繼續推動綠色低碳轉型,通過技術創新和產業鏈延伸,提升產品附加值,實現高質量發展。 劉興旭先生指出:中國心連心將憑藉其技術研發優勢,致力於推動化工新材料和精細化工的發展,以滿足市場對高性能、高附加值產品的需求,確保集團的長遠可持續發展。通過優化產品結構和提升資源利用率,集團將實現更高的市場競爭力和可持續發展目標。 ~ 完 ~ 關於中國心連心化肥有限公司 中國心連心化肥有限公司為中國最具規模優勢和成本效益的煤基尿素生產商之一,主要從事尿素、複合肥、甲醇、二甲醚、三聚氰胺、糠醇、糠醛、2-甲基呋喃和醫藥中間體等相關差異化產品的研發、生產與銷售。集團堅持「總成本領先、差異化競爭」的發展策略,做大做強化肥主業,依託新鄉、新疆、江西等地區資源,向上遊新能源、新材料等產品鏈延伸,向煤化工相關多元化方向發展。中國心連心股份在香港交易所主機板上市,股份編號:01866.HK。 投資者及媒體查詢 中國心連心化肥有限公司 桂琳 電話:86-135 6942 3415 電郵:lin.gui@chinaxlx.com.hk 中國公關顧問有限公司 陳秋玲 電話:852-2522 1368 / 852-2522 1838 電郵:rchen@prchina.com.hk 文件: 【新聞稿】中國心連心公佈2024年首三季度業績 2024-10-31 此財經新聞稿由EQS Group via SEAPRWire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php
More